CXCL12 and neoplasm: Treatment with this formulation trapped CXCL12 and altered the immune landscape of orthotopic KPC allografts, most notably through the induction of a pronounced CD8+ T cell infiltrate that primed tumours for checkpoint inhibition with a co-delivered PDL1 trap.